4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Roles of Mesenchymal Stem Cells in Gastrointestinal Cancers

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Mesenchymal stem cells (MSCs) were reported to have strong immunomodulatory ability, and inhibit the proliferation of T cells and their immune response through cell-to-cell interactions and the generation of cytokines. With high differentiation potential and self-renewal ability, MSCs are considered to function in alleviating inflammatory responses, promoting tissue regeneration and inhibiting tissue fibrosis formation. As the most common malignancies, gastrointestinal (GI) cancers have high incidence and mortality. The accurate diagnosis, exact prognosis and treatment of GI cancers have always been a hot topic. Therefore, the potential applications of MSCs in terms of GI cancers are receiving more and more attention. Recently, there is increasing evidence that MSCs may serve as a key point in the growth, metastasis, inhibition, treatment and prognosis of GI cancers. In this review, we summarized the roles of MSCs in GI cancers, mainly focusing on esophageal cancer (EC), gastric cancer (GC), liver cancer (LC), colorectal cancer (CRC) and pancreatic cancer. Besides, we proposed MSCs as potential targets and treatment strategies for the effective treatment of GI cancers, which may provide better guidance for the clinical treatment of GI cancers.

          Related collections

          Most cited references132

          • Record: found
          • Abstract: found
          • Article: not found

          First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

          Nivolumab has been associated with longer overall survival than docetaxel among patients with previously treated non-small-cell lung cancer (NSCLC). In an open-label phase 3 trial, we compared first-line nivolumab with chemotherapy in patients with programmed death ligand 1 (PD-L1)-positive NSCLC.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Global Burden of 5 Major Types Of Gastrointestinal Cancer

            There were an estimated 4.8 million new cases of gastrointestinal (GI) cancers and 3.4 million related deaths, worldwide, in 2018. GI cancers account for 26% of the global cancer incidence and 35% of all cancer-related deaths. We investigated the global burden from the 5 major GI cancers, as well as geographic and temporal trends in cancer-specific incidence and mortality.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

              Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma on the basis of recurrence-free and overall survival rates that were higher than those with placebo in a phase 3 trial. We wanted to determine the efficacy of nivolumab versus ipilimumab for adjuvant therapy in patients with resected advanced melanoma.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Immunol
                Front Immunol
                Front. Immunol.
                Frontiers in Immunology
                Frontiers Media S.A.
                1664-3224
                24 February 2022
                2022
                : 13
                : 844001
                Affiliations
                [1] 1 School of Medicine, Zhejiang University , Hangzhou, China
                [2] 2 Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine , Hangzhou, China
                [3] 3 College of Life Sciences and Medicine, Zhejiang Sci-Tech University , Hangzhou, China
                [4] 4 Department of Clinical Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University , Suzhou, China
                Author notes

                Edited by: Robert Chunhua Zhao, Chinese Academy of Medical Sciences and Peking Union Medical College, China

                Reviewed by: Zhenjian Zhuo, Guangzhou Medical University, China; Philippe Lewalle, Jules Bordet Institute, Belgium; Guopan Liu, City University of Hong Kong, Hong Kong SAR, China

                *Correspondence: Jian Wu, wujianglinxing@ 123456163.com

                †These authors have contributed equally to this work

                This article was submitted to Alloimmunity and Transplantation, a section of the journal Frontiers in Immunology

                Article
                10.3389/fimmu.2022.844001
                8907448
                35281017
                28d4900d-e72f-41b4-9e19-9b1568df0c02
                Copyright © 2022 Xiang, Hua, Hao, Biao, Zhu, Zhai and Wu

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 27 December 2021
                : 03 February 2022
                Page count
                Figures: 1, Tables: 2, Equations: 0, References: 132, Pages: 13, Words: 6424
                Categories
                Immunology
                Review

                Immunology
                mesenchymal stem cells,gastrointestinal cancers,bilateral roles,mediating mechanism,therapeutic targets

                Comments

                Comment on this article